AMO Pharma Announces Collaboration with Population Health Research Institute to Advance Proof of Concept Clinical Trial to Assess Efficacy of Tideglusib in Treatment of Arrhythmogenic Cardiomyopathy

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

AMO-Collaboration

More Like This

PR Newswire associated0

AMO Pharma Enters into License Agreement with Population Health Research Institute (PHRI) and Venca Research Inc. to Advance Largest-Ever Study in Treatment of Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)

PR Newswire associated0

AMO Pharma Completes Meeting with U.S. FDA and Outlines Plans to Advance Clinical Development of AMO-02 (tideglusib) in Treatment of Myotonic Dystrophy

PR Newswire associated0

AMO Pharma Announces Preclinical Data Showing AMO-02 Improves Muscle Function, Glucose Handling and CNS function in Mouse Models of Duchenne Muscular Dystrophy

PR Newswire associated0

AMO Pharma Reports Long-Term Safety Data from REACHCDM-X Study of AMO-02 in Treatment of Congenital Myotonic Dystrophy Type 1

Prothena Announces that Novo Nordisk Will Advance Coramitug (Formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with Cardiomyopathy

Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial

Amplo Biotechnology Announces Three Presentations at the European Society of Gene and Cell Therapy 31st Annual Congress

Chiesi Group and Arbor Biotechnologies Announce a Global Strategic Partnership to Develop Novel Rare Disease Gene Editing Programmes